RGD-DA6

• Description:

  RGD-DA6 is an αvβ3-targeted ligand. RGD-DA6 consists of RGDfK (an integrin αvβ3-targeted RGD peptide), DOTADG, d-Glu, Lys, AMBA, and IPBA. RGD-DA6 can be radiolabeled as an αvβ3-targeted radioligand and used for high-contrast tumor imaging and enhanced anticancer efficacy[1].

• UNSPSC:

  12352005

• Target:

  Integrin

• Related Pathways:

  Cytoskeleton

• Field of Research:

  Cancer

• Smiles:

  O=C (NCCCC[C@@H]1NC ([C@H] (NC ([C@@H] (NC (CNC ([C@@H] (NC1=O) CCCNC (N) =N) =O) =O) CC (O) =O) =O) CC2=CC=CC=C2) =O) CCC (N (CCN (CC3) CC (O) =O) CCN (CC (O) =O) CCN3C (CCC (N[C@@H] (C (N[C@@H] (CCCCNC (C4=CC=C (C=C4) CNC (CCCC5=CC=C (C=C5) I) =O) =O) C (O) =O) =O) CCC (O) =O) =O) C (O) =O) C (O) =O

• Molecular Formula:

  C78H110IN17O24

• Molecular Weight:

  1796.71

• References & Citations:

  [1]Kazuta N, et al. Development of Novel Integrin αvβ3‑Targeted Radioligand for Enhanced Tumor Accumulation. ACS Med Chem Lett. 2025 Jun 30;16 (7) :1346-1353.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported